TY-2136b / TYK Medicines, Livzon Pharma - LARVOL DELTA

Orphan Designation: Treatment of ALK-positive, ROS1-positive, NTRK fusion-positive, or LTK positive non-small cell lung cancer (FDA) - Date Designated: 09/19/2023

Orphan drug • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations (clinicaltrials.gov) - P1 | N=282 | Recruiting | Sponsor: TYK Medicines, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • NTRK1 • NTRK2 • NTRK3 • ROS1

TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations (AACR 2023) - "Meanwhile, TY-2136b, TPX-0005, and TRK-selective second-generation LOXO-195 inhibitors had similar activity against TRKA G595R and TRKC G623R resistance mutations, but TY-2136b was better than TPX-0005 and LOXO-195 against TRKA G595R/F589L dual mutations in vitro. In vivo studies, TY-2136b showed dose-dependent anti-tumor effect at the dose of 5, 10, and 20 mg/kg, bid, in xenograft tumor models carrying ROS1 G2032R and TRKA G595R mutation, and was more effective than Crizotinib and LOXO-101 at testing dose, and showed better efficacy than TPX-0005 in higher dose...Currently, TY-2136b is under first-in-human clinical investigations in the US and China. * To Whom Correspondence should be addressed to: Jun Li, Chengshan Niu and Yusheng Wu"

Tumor cell • Oncology • ALK • CD74 • NTRK3 • ROS1 • TPM3

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations (clinicaltrials.gov) - P1 | N=282 | Not yet recruiting | Sponsor: TYK Medicines, Inc

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • NTRK1 • NTRK2 • NTRK3 • ROS1